- Home
- CDNL vs EYPT Comparison
CDNL vs EYPT Comparison
Compare CDNL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CDNL | EYPT |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CDNL | EYPT |
|---|---|---|
| Price | $39.23 | $4.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $38.00 | $31.80 |
| AVG Volume (30 Days) | 705.1K | ★ 1.7M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $456,045,369.00 | $7,539,000.00 |
| Revenue This Year | $50.30 | N/A |
| Revenue Next Year | $8.41 | $3,115.57 |
| P/E Ratio | $74.38 | ★ N/A |
| Revenue Growth | ★ 44.69 | N/A |
| 52 Week Low | $21.98 | $9.65 |
| 52 Week High | $96.40 | $19.11 |
Technical Indicators
Market Signals| Indicator | CDNL | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 29.83 | 24.52 |
| Support Level | $24.46 | N/A |
| Resistance Level | $65.55 | $15.31 |
| Average True Range (ATR) | 4.77 | 0.91 |
| MACD | -2.64 | -0.38 |
| Stochastic Oscillator | 13.99 | 5.21 |
Price Performance
Historical ComparisonAbout CDNL Cardinal Infrastructure Group Inc. Class A Common Stock
Cardinal Infrastructure Group Inc provides a comprehensive suite of infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. The company provides wet utility installations (water, sewer, and stormwater systems), as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. It derives all revenue in the United States of America from construction projects based in North Carolina and South Carolina.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.